Miyoshi myopathy is an autosomal recessive distal myopathy with predominant involvement of the posterior calf muscles attributed to mutations in the dysferlin gene. We report a 26-year-old male, born of nonconsanginous parentage. He noticed weakness and atrophy of leg muscles with inability to walk on his heels. The creatine kinase concentration was high. The electromyography showed myopathic pattern and the muscle biopsy disclosed dystrophic changes with absence of dysferlin. Miyoshi myopathy may be distinct among the hereditary distal myopathies. There are only few reported cases of Miyoshi myopathy in the world literature. In India only 12 cases were reported who had classical features of Miyoshi myopathy. Our's is a typical case of Miyoshi myopathy, with an affected twin sister as well. He also had "calf heads on a trophy sign" on physical examination, which is considered to be pathognomonic of this disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481807 | PMC |
| http://dx.doi.org/10.4103/0976-3147.158798 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Presentation, Diagnosis, and Genetic Insights of Miyoshi Myopathy: A Case Report and Literature Review.
Cureus
September 2024
Neurology, Marek Kulma Praktyka Lekarska, Gorzkowice, POL.
Article Synopsis
- Miyoshi myopathy (MM) is a rare genetic disorder due to mutations in the dysferlin gene, linked to muscle degeneration and recognized as the same disease as Lower Girdle Muscular Dystrophy R2 (LGMD2B).
- A 44-year-old male patient started experiencing symptoms at 19, including difficulties with stairs and toe-standing, leading to observable muscle atrophy and walking issues over the years.
- The diagnosis was confirmed through genetic testing, revealing a mutation in the DYSF gene, and highlights the critical role of genetic diagnostics and the need for further research in muscular dystrophies.*
Performance of upper limb entry item to predict forced vital capacity in dysferlin-deficient limb girdle muscular dystrophy.
Neuromuscul Disord
October 2024
The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon, Tyne, United Kingdom. Electronic address:
Dysferlin-deficient limb girdle muscular dystrophy (LGMD R2), also referred to as dysferlinopathy, can be associated with respiratory muscle weakness as the disease progresses. Clinical practice guidelines recommend biennial lung function assessments in patients with dysferlinopathy to screen for respiratory impairment. However, lack of universal access to spirometry equipment and trained specialists makes regular monitoring challenging.
View Article and Find Full Text PDFBrain of miyoshi myopathy/dysferlinopathy patients presents with structural and metabolic anomalies.
Sci Rep
August 2024
Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia.
Article Synopsis
- Miyoshi myopathy/dysferlinopathy (MMD) is a rare muscle disease linked to mutations in the DYSF gene, which also affects the brain's structure and function, although this impact hasn't been fully studied.
- Using MRI techniques, a family study revealed significant differences in the brain of MMD patients, including an asymmetrical increase in the size of their inferior lateral ventricles and notable decreases in magnesium levels and energy metabolism in brain regions like the hippocampus.
- Following a month of magnesium supplementation, the MMD patients showed improvements, suggesting potential benefits and calling for more research into the brain functions of MMD patients and further testing of magnesium therapy.
Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.
Int J Mol Sci
May 2024
Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA 6150, Australia.
Dysferlin is a large transmembrane protein involved in critical cellular processes including membrane repair and vesicle fusion. Mutations in the dysferlin gene () can result in rare forms of muscular dystrophy; Miyoshi myopathy; limb girdle muscular dystrophy type 2B (LGMD2B); and distal myopathy. These conditions are collectively known as dysferlinopathies and are caused by more than 600 mutations that have been identified across the gene to date.
View Article and Find Full Text PDFThe Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.
Biomolecules
February 2024
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Dysferlinopathies refer to a spectrum of muscular dystrophies that cause progressive muscle weakness and degeneration. They are caused by mutations in the gene, which encodes the dysferlin protein that is crucial for repairing muscle membranes. This review delves into the clinical spectra of dysferlinopathies, their molecular mechanisms, and the spectrum of emerging therapeutic strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!